Venus Medtech (Hangzhou) Inc. (2500.HK) HKSE

2.87

-0.05(-1.71%)

Updated at October 15 04:08PM

Currency In HKD

Venus Medtech (Hangzhou) Inc.

Address

No. 88, Jiangling Road

Hangzhou, 31005

China

Phone

86 57 1877 72180

Sector

Healthcare

Industry

Medical - Devices

Employees

691

First IPO Date

December 10, 2019

Key Executives

NameTitlePayYear Born
Ms. Meirong LiuVice President & Executive Director1.89M1976
Mr. Liqiao MaVice President of clinical medicine & Executive Director2.09M1985
Mr. Hou-Sen Lim MEng.GM & Executive Director3.03M1975
Joyce HeoDirector of Sales0N/A
Mr. Wai Chiu Wong C.P.A., CTP, FCSCompany Secretary01956
Mr. Christopher Lee RichardsonHead of U.S. Operations01962
Mr. Amir GrossHead of Venus Global Heart Valve Innovation Center0N/A
Shakeel OsmanHead of International Congenital Heart Disease Business0N/A
Mr. Zhu BingChief Financial Officer01965

Description

Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.